Further licence extension for adalimumab in arthritis

Humira is the first biologic specifically licensed for use in non-radiographic severe axial spondyloarthritis.

The recommended adult dose of Humira in ankylosing spondylitis is 40mg as a single subcutaneous injection every two weeks | SCIENCE PHOTO LIBRARY
The recommended adult dose of Humira in ankylosing spondylitis is 40mg as a single subcutaneous injection every two weeks | SCIENCE PHOTO LIBRARY
Humira (adalimumab) is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS who have objective signs of inflammation (elevated CRP and/or MRI) and who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).

In the Phase III trial (ABILITY-1), patients with active non-radiographic axial spondyloarthritis were randomised to receive either adalimumab (n=91) 40mg by subcutaneous injection or placebo (n=94) every other week for 12 weeks.

Significant improvement in disease signs and symptoms, defined as a minimum 40% improvement from baseline in the Assessment of SpondyloArthritis International Society (ASAS) response criteria, was seen at week 12 in a greater proportion of the adalimumab group than the placebo group (36% vs 15%, p<0.001).

View Humira drug record
 
Further information: AbbVie Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more